The reasons for triple therapy in stable COPD patients in Japanese clinical practice

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1053-1059

  Miyazaki, Masaki ^a   Nakamura, Hidetoshi ^a,b   Takahashi, Saeko ^a   Chubachi, Shotaro ^a   Sasaki, Mamoru ^a   Haraguchi, Mizuha ^a   Terai, Hideki ^a   Ishii, Makoto ^a   Fukunaga, Koichi ^a   Tasaka, Sadatomo ^a   Soejima, Kenzo ^a   Asano, Koichiro ^c   Betsuyaku, Tomoko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Long acting muscarinic antagonists; Long acting 2 agonists; Triple therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; FEMALE; HUMAN; JAPANESE (PEOPLE); MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRESCRIPTION; RETROSPECTIVE STUDY; SPIROMETRY; TREATMENT INDICATION; COMBINATION DRUG THERAPY; CONVALESCENCE; DRUG EFFECTS; JAPAN; LUNG; MEDICAL RECORD; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; LUNG; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SELECTION; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84933574007     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S79864     Document Type: Article

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed December 6, 2014.
2. Fukahori S, Matsuse H, Takamura N, et al. Prevalence of chronic obstructive pulmonary diseases in general clinics in terms of FEV1/FVC. Int J Clin Pract. 2009;63(2):269-274.
3. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555.
4. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006;11(5):598-602.
5. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63(7):592-598.
6. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741-750.
7. Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res. 2012;13:15.
8. Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012;25(1):40-47.
9. Cazzola M, Matera MG. Triple combinations in chronic obstructive pulmonary disease-is three better than two? Expert Opin Pharmacother. 2014;15(17):2475-2478.
10. Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15:13.
11. Chubachi S, Nakamura H, Sasaki M, et al. Polymorphism of low-density lipoprotein receptor-related protein 5 gene and emphysema severity are associated with osteoporosis in Japanese patients with or at risk for COPD. Respirology. Epub 2014 Nov 12.
12. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.
13. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9):e105296.
14. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889-905.
15. Koblizek V, Pecen L, Zatloukal J, et al. Real-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatment. PLoS One. 2014;9(11):e111078.
16. Park SJ, Make B, Hersh CP, Bowler RP. Significance of medication history at the time of entry into the COPDGene study: relationship with exacerbation and CT metrics. COPD. Epub 2014 Sep 25.
17. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-1294.
18. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761-767.
19. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(3):418-424.
20. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44-52.
21. Kim SR, Rhee YK. Overlap between asthma and COPD: where the two diseases converge. Allergy Asthma Immunol Res. 2010;2(4):209-214.
22. Suzuki M, Makita H, Ito YM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014;43(5):1289-1297.
23. Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S. Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir Res. 2014;15:141.
24. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62(11):932-937.
25. Tanabe N, Muro S, Hirai T, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(12):1653-1659.
26. Betsuyaku T, Kato M, Fujimoto K, et al. A study to assess COPD symptom-based management and to optimise treatment strategy in Japan (COSMOS-J) based on GOLD 2011. Int J Chron Obstruct Pulmon Dis.2013;8:453-459.